Revenues declined 9% year over year to £32.1 million in H1 2019 while operating EBITDA was a loss of £1.4 million. Cash generated from operations in H1 2019 was £1.3 million compared to £18.3 million in the year-ago period. Cash at 30 June 2019 was £26.1 million compared to £32.2 million at 31 December 2018.
The company entered into an R&D collaboration with Santen Pharmaceutical Co Ltd for a retinal disease during the reported period.
On 4th September 2019, at the time of writing, GMT 11:51 AM, OXB shares were quoted at GBX 623, down 16 points or 2.50% over the previous day closing price.